Global Microbial Fermentation Technology Market To Reach $45.2 Billion By 2030


(MENAFN- GlobeNewsWire - Nasdaq)

New York, May 25, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Microbial Fermentation Technology Industry" -
Antibiotics, one of the segments analyzed in the report, is projected to record a 7.4% CAGR and reach US$16.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Enzymes segment is readjusted to a revised 3.4% CAGR for the next 8-year period.
The U.S. Market is Estimated at $8.2 Billion, While China is Forecast to Grow at 9.2% CAGR
The Microbial Fermentation Technology market in the U.S. is estimated at US$8.2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.2 Billion by the year 2030 trailing a CAGR of 9.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 4.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.2 Billion by the year 2030.
Select Competitors (Total 44 Featured)
- Amyris, Inc.
- Biocon Ltd.
- BioVectra Inc.
- Danone UK
- F. Hoffmann-La Roche AG
- Koninklijke DSM NV
- Lonza Group AG
- Novozymes A/S
- TerraVia Holdings, Inc.
- United Breweries Ltd.
Read the full report:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Microbial Fermentation Technology - Global Key Competitors
Percentage Market Share in 2020 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2020 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Microbial Fermentation Technology Market
Analysis of Annual Sales in US$ Million for Years 2014 through
2030
Table 2: World Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2022 through 2030 and % CAGR
Table 3: World Historic Review for Microbial Fermentation
Technology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2014 through 2021 and % CAGR
Table 4: World 16-Year Perspective for Microbial Fermentation
Technology by Geographic Region - Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2014,
2023 & 2030
Table 5: World Recent Past, Current & Future Analysis for
Antibiotics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR
Table 6: World Historic Review for Antibiotics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2014 through 2021
and % CAGR
Table 7: World 16-Year Perspective for Antibiotics by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 8: World Recent Past, Current & Future Analysis for
Enzymes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR
Table 9: World Historic Review for Enzymes by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2014 through 2021
and % CAGR
Table 10: World 16-Year Perspective for Enzymes by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 11: World Recent Past, Current & Future Analysis for
Recombinant Proteins by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR
Table 12: World Historic Review for Recombinant Proteins by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR
Table 13: World 16-Year Perspective for Recombinant Proteins by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 14: World Recent Past, Current & Future Analysis for
Monoclonal Antibodies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Revenues in
US$ Million for Years 2022 through 2030 and % CAGR
Table 15: World Historic Review for Monoclonal Antibodies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR
Table 16: World 16-Year Perspective for Monoclonal Antibodies
by Geographic Region - Percentage Breakdown of Value Revenues
for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa for Years 2014, 2023 & 2030
Table 17: World Recent Past, Current & Future Analysis for
Small Molecules by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR
Table 18: World Historic Review for Small Molecules by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR
Table 19: World 16-Year Perspective for Small Molecules by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 20: World Recent Past, Current & Future Analysis for
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR
Table 21: World Historic Review for Vaccines by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2014 through 2021
and % CAGR
Table 22: World 16-Year Perspective for Vaccines by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 23: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR
Table 24: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR
Table 25: World 16-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 26: World Recent Past, Current & Future Analysis for
Contract Development & Manufacturing Organizations (CDMOs) by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2022 through 2030 and % CAGR
Table 27: World Historic Review for Contract Development &
Manufacturing Organizations (CDMOs) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR
Table 28: World 16-Year Perspective for Contract Development &
Manufacturing Organizations (CDMOs) by Geographic Region -
Percentage Breakdown of Value Revenues for USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa for Years 2014, 2023 & 2030
Table 29: World Recent Past, Current & Future Analysis for
Biopharmaceutical Companies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Revenues in
US$ Million for Years 2022 through 2030 and % CAGR
Table 30: World Historic Review for Biopharmaceutical Companies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Revenues in US$ Million for
Years 2014 through 2021 and % CAGR
Table 31: World 16-Year Perspective for Biopharmaceutical
Companies by Geographic Region - Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030
Table 32: World Recent Past, Current & Future Analysis for
Contract Research Organizations (CROs) by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2022 through 2030 and % CAGR
Table 33: World Historic Review for Contract Research
Organizations (CROs) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2014 through 2021 and % CAGR
Table 34: World 16-Year Perspective for Contract Research
Organizations (CROs) by Geographic Region - Percentage
Breakdown of Value Revenues for USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa for
Years 2014, 2023 & 2030
Table 35: World Recent Past, Current & Future Analysis for
Academic & Research Institutes by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2022 through 2030 and % CAGR
Table 36: World Historic Review for Academic & Research
Institutes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2014 through 2021 and % CAGR
Table 37: World 16-Year Perspective for Academic & Research
Institutes by Geographic Region - Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030
III. MARKET ANALYSIS
UNITED STATES
Microbial Fermentation Technology Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United States
for 2023 (E)
Table 38: USA Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application - Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 39: USA Historic Review for Microbial Fermentation
Technology by Application - Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR
Table 40: USA 16-Year Perspective for Microbial Fermentation
Technology by Application - Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030
Table 41: USA Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use - Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 42: USA Historic Review for Microbial Fermentation
Technology by End-Use - Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR
Table 43: USA 16-Year Perspective for Microbial Fermentation
Technology by End-Use - Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030
CANADA
Table 44: Canada Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application - Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 45: Canada Historic Review for Microbial Fermentation
Technology by Application - Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR
Table 46: Canada 16-Year Perspective for Microbial Fermentation
Technology by Application - Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030
Table 47: Canada Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use - Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 48: Canada Historic Review for Microbial Fermentation
Technology by End-Use - Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR
Table 49: Canada 16-Year Perspective for Microbial Fermentation
Technology by End-Use - Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030
JAPAN
Microbial Fermentation Technology Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 50: Japan Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application - Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 51: Japan Historic Review for Microbial Fermentation
Technology by Application - Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR
Table 52: Japan 16-Year Perspective for Microbial Fermentation
Technology by Application - Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030
Table 53: Japan Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use - Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 54: Japan Historic Review for Microbial Fermentation
Technology by End-Use - Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR
Table 55: Japan 16-Year Perspective for Microbial Fermentation
Technology by End-Use - Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030
CHINA
Microbial Fermentation Technology Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in China for 2023 (E)
Table 56: China Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application - Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 57: China Historic Review for Microbial Fermentation
Technology by Application - Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR
Table 58: China 16-Year Perspective for Microbial Fermentation
Technology by Application - Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030
Table 59: China Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use - Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 60: China Historic Review for Microbial Fermentation
Technology by End-Use - Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR
Table 61: China 16-Year Perspective for Microbial Fermentation
Technology by End-Use - Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030
EUROPE
Microbial Fermentation Technology Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Table 62: Europe Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Geographic Region -
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets - Independent Analysis of Annual Revenues in US$
Million for Years 2022 through 2030 and % CAGR
Table 63: Europe Historic Review for Microbial Fermentation
Technology by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Revenues in US$ Million for Years 2014 through 2021
and % CAGR
Table 64: Europe 16-Year Perspective for Microbial Fermentation
Technology by Geographic Region - Percentage Breakdown of Value
Revenues for France, Germany, Italy, UK, Spain, Russia and Rest
of Europe Markets for Years 2014, 2023 & 2030
Table 65: Europe Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application - Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 66: Europe Historic Review for Microbial Fermentation
Technology by Application - Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR
Table 67: Europe 16-Year Perspective for Microbial Fermentation
Technology by Application - Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030
Table 68: Europe Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use - Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 69: Europe Historic Review for Microbial Fermentation
Technology by End-Use - Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR
Table 70: Europe 16-Year Perspective for Microbial Fermentation
Technology by End-Use - Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030
FRANCE
Microbial Fermentation Technology Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in France for 2023 (E)
Table 71: France Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application - Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 72: France Historic Review for Microbial Fermentation
Technology by Application - Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR
Table 73: France 16-Year Perspective for Microbial Fermentation
Technology by Application - Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030
Table 74: France Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use - Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 75: France Historic Review for Microbial Fermentation
Technology by End-Use - Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR
Table 76: France 16-Year Perspective for Microbial Fermentation
Technology by End-Use - Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030
GERMANY
Microbial Fermentation Technology Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 77: Germany Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application - Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 78: Germany Historic Review for Microbial Fermentation
Technology by Application - Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR
Table 79: Germany 16-Year Perspective for Microbial
Fermentation Technology by Application - Percentage Breakdown
of Value Revenues for Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications for the Years 2014, 2023 & 2030
Table 80: Germany Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use - Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 81: Germany Historic Review for Microbial Fermentation
Technology by End-Use - Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR
Table 82: Germany 16-Year Perspective for Microbial
Fermentation Technology by End-Use - Percentage Breakdown of
Value Revenues for Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes for the Years 2014, 2023 & 2030
ITALY
Table 83: Italy Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application - Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 84: Italy Historic Review for Microbial Fermentation
Technology by Application - Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR
Table 85: Italy 16-Year Perspective for Microbial Fermentation
Technology by Application - Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030
Table 86: Italy Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use - Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 87: Italy Historic Review for Microbial Fermentation
Technology by End-Use - Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR
Table 88: Italy 16-Year Perspective for Microbial Fermentation
Technology by End-Use - Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030
UNITED KINGDOM
Microbial Fermentation Technology Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United Kingdom
for 2023 (E)
Table 89: UK Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application - Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 90: UK Historic Review for Microbial Fermentation
Technology by Application - Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR
Table 91: UK 16-Year Perspective for Microbial Fermentation
Technology by Application - Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030
Table 92: UK Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use - Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 93: UK Historic Review for Microbial Fermentation
Technology by End-Use - Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR
Table 94: UK 16-Year Perspective for Microbial Fermentation
Technology by End-Use - Percentage Breakdown of Value Revenues
for Contract Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes for the Years 2014,
2023 & 2030
SPAIN
Table 95: Spain Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by Application - Antibiotics,
Enzymes, Recombinant Proteins, Monoclonal Antibodies, Small
Molecules, Vaccines and Other Applications - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 96: Spain Historic Review for Microbial Fermentation
Technology by Application - Antibiotics, Enzymes, Recombinant
Proteins, Monoclonal Antibodies, Small Molecules, Vaccines and
Other Applications Markets - Independent Analysis of Annual
Revenues in US$ Million for Years 2014 through 2021 and % CAGR
Table 97: Spain 16-Year Perspective for Microbial Fermentation
Technology by Application - Percentage Breakdown of Value
Revenues for Antibiotics, Enzymes, Recombinant Proteins,
Monoclonal Antibodies, Small Molecules, Vaccines and Other
Applications for the Years 2014, 2023 & 2030
Table 98: Spain Recent Past, Current & Future Analysis for
Microbial Fermentation Technology by End-Use - Contract
Development & Manufacturing Organizations (CDMOs),
Biopharmaceutical Companies, Contract Research Organizations
(CROs) and Academic & Research Institutes - Independent
Analysis of Annual Revenues in US$ Million for the Years 2022
through 2030 and % CAGR
Table 99: Spain Historic Review for Microbial Fermentation
Technology by End-Use - Contract Development & Manufacturing
Organizations (CDMOs), Biopharmaceutical Companies, Contract
Research Organizations (CROs) and Academic & Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Million for Years 2014 through 2021 and % CAGR
Table 100: Spain 16-Year Perspective for Microbial Fermentation
Technology by End-Use - Percentage Breakdown of Value Revenues
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report:
About reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________




MENAFN25052023004107003653ID1106316238


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.